This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) Platinum complex of the general formula I:



(I)

in which

R = 2H, ---, -$(CH_2)_i$- (i = 2 or 3);

X = O or NH;

Y = O, S or 2 H;

m = 0 to 5;

n = 0 to 6;

PM denotes a protein-binding group.

2. (Original) Platinum complex as claimed in claim 1, characterized in that PM is a maleinimide group, a 2-dithiopyridyl group, a halogen acetamide group, a halogen acetate group, a disulfide group, an acrylic acid ester group, a monoalkylmaleic acid ester group, a monoalkylmaleaminic acid amide group, an N-hydroxysuccinimidyl ester group, an isothiocyanate group or an aziridine group which can be optionally substituted.

3. (Original) Platinum complex as claimed in claim 2, characterized in that PM is a maleinimide group which can be optionally substituted.

4. (Original) Platinum complex as claimed in claim 3, characterized in that m < 2 and n = 1 to 4.

5. (Original) Platinum complex as claimed in claim 4, characterized in that X = O and Y = O.

6. (Currently Amended) Process for producing platinum complexes as claimed in ~~one of the previous claims~~ Claim 1, characterized in that a cyclobutane-1,1-dicarboxylic acid derivative of the general formula IV



(IV)

in which

X = O or NH

Y = O, S or 2 H

m = 0 to 5

n = 0 to 6

and PM denotes a protein-binding group, is reacted with a platinum complex of the general formula V



(V)

in which

R = 2 H, -- -(CH$_2$)$_i$- (i = 2 or 3)

R' = 2 NO_2, SO_2 or CO.

7. (Original) Process as claimed in claim 6, characterized in that the cyclobutane-1,1-dicarboxylic acid derivative of the general formula II is obtained by reacting a 4-methoxybenzyl-protected cyclobutane-1,1-dicarboxylic acid derivative of the general formula VII



(VII)

in which

X = O or NH

Y = O, S or 2H

m = 0 to 5

n = 0 to 6

and PM denotes a protein-binding group, with trifluoroacetic acid and anisole.

8. (Original) Process as claimed in claim 7, characterized in that the cyclobutane-1,1-dicarboxylic acid derivative of the general formula VII is obtained by reacting bis(4-methoxybenzyl)-3-hydroxycyclobutane-1,1-dicarboxylate with a heterobifunctional cross-linker of the general formula VI



(VI)

in which

n = 0, 1

m= 1 to 6

and PM denotes a protein-binding group, in the presence of carboxylic acid activation reagents.

9. (Original) Process as claimed in claim 8, characterized in that *N,N'*-dicyclohexylcarbodiimide, *N,N'*-diisopropylcarbodiimide or (benzotriazole-1-yloxy)tris(dimethylamino)phosphonium hexafluoro-phosphate and most preferably 2-chloro-1-methylpyridinium iodide are used as carboxylic acid activation reagents.

10. (Currently Amended) Process as claimed in claim 8 ~~or 9~~, characterized in that bis(4-methoxybenzyl)-3-hydroxycyclobutane-1,1-dicarboxylate is reacted with a maleinimidocarboxylic acid of the general formula VIa



(VIa)

in which
n = 0, 1
m = 1 to 6
using 2-chloro-1-methylpyridinium iodide.

11. (Original) Process as claimed in claim 8, characterized in that bis(4-methoxybenzyl)-3-hydroxycyclobutane-1,1-dicarboxylate is obtained by reacting bis(4-methoxybenzyl)-3-*tert.*-butyldimethylsiloxycyclobutane-1,1-dicarboxylate with tetrabutylammonium fluoride.

12. (Original) Process as claimed in claim 11, characterized in that bis(4-methoxybenzyl)-3-*tert.*-butyldimethylsiloxycyclobutane-1,1-dicarboxylate is obtained by reacting bis(4-methoxybenzyl)malonate with 1,3-dibromo-2-*tert.*-butyldimethylsiloxypropane.

13. (Currently Amended) Pharmaceutical preparation containing a platinum complex according to ~~any one of the claims 1 to 5~~ Claim 1 as an active ingredient, optionally together with common auxiliary substances and/or pharmaceutical solvents.

14. (Currently Amended) Use of a platinum complex as claimed in ~~any one of the claims 1 to 5~~ Claim 1 for the treatment of cancer diseases.

15. (Currently Amended) Process for producing a pharmaceutical preparation for treating cancer diseases, characterized in that a compound as claimed in ~~any one of the claims 1 to 5~~ Claim 1 is transferred into a therapeutically acceptable solution.